Atlas Trials

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Clinical trial NCT03249714 · COMPLETED

Trial details

NCT number
NCT03249714
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsing Multiple Sclerosis
Start date
2018-03-15
Primary completion
2019-12-26
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.